Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

NCT06855095 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT06855095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06855095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 25, 2024
Completion date
March 1, 2027
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine neoplasm, neuroendocrine tumor grade 1, neuroendocrine tumor grade 2, neuroendocrine tumors